Registration Opens for Workshop on Conflicts of Interests
The European Medicines Agency (EMA) is inviting expressions of interest in its workshop on Conflicts of Interests on 6 September 2013.
The workshop, entitled 'Best expertise vs conflicts of interests: Striking the right balance', is intended to elicit the views and concerns from academia, patient organizations, Committee representatives, NGOs, the pharmaceutical industry and the scientific media on the Agency’s current conflicts of interests policy. Representatives from national competent authorities, European Union (EU) institutions and other agencies will also attend the workshop.
During the last years, the EMA has taken comprehensive steps to strengthen its handling of conflicts of interests. This was acknowledged by both the European Parliament and the European Court of Auditors, which found that, despite highlighting some areas for further improvement, the Agency now has some of the most advanced policies and procedures among EU agencies for declaring, assessing and managing potential conflicts of interests.
The main challenge in operating the strengthened procedures is how to achieve the right balance between ensuring the impartiality and independence of experts involved in the Agency’s work, versus the need to secure the best-possible scientific expertise to continually deliver high quality scientific assessments.
Feedback from stakeholders at the workshop will help to define and analyse the extent of the challenge, and will assist the Agency to find the most appropriate solutions to address this.
Expressions of interest to attend the workshop should be sent to [email protected] by Thursday, 1 August 2013. Please include your name, title and organization in your email. Places are limited and will be allocated to ensure a fair representation across all stakeholder groups and organisations.
The workshop will be held from 10:30 to 16:30 at the European Medicines Agency in Canary Wharf, London.
The agenda of the workshop will be available shortly.
The outcomes of the workshop and presentations will be published on this website.
A live broadcast of the workshop will be available.
Related News
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance